Cetuximab sarotalocan (Cetuximab-IRDye-700DX) is a conjugate comprising Cetuximab, an anti-EGFR monoclonal antibody, and IRdye700DX, a near-infrared photosensitizing dye. It is utilized in the study of head and neck cancers [1] [2].

Cetuximab sarotalocan sodium, an antibody-photosensitive complex, combines Cetuximab, an epidermal growth factor receptor monoclonal antibody, with the dye IRdye700DX, a photosensitive substance. After administration, illumination with a red light at 690 nm [2] specifically destroys only the tumor cells.